2022
Direct oral anticoagulants in pediatric venous thromboembolism: Experience in specialized pediatric hemostasis centers in the United States
Corrales-Medina F, Raffini L, Recht M, Santos J, Thornburg C, Davila J, Investigators A. Direct oral anticoagulants in pediatric venous thromboembolism: Experience in specialized pediatric hemostasis centers in the United States. Research And Practice In Thrombosis And Haemostasis 2022, 7: 100001. PMID: 36970740, PMCID: PMC10031368, DOI: 10.1016/j.rpth.2022.100001.Peer-Reviewed Original ResearchPrevention of venous thromboembolismVenous thromboembolismOral anticoagulantsPediatric hematologistsClinically relevant nonmajor bleeding eventsTreatment of acute venous thromboembolismSecondary prevention of venous thromboembolismUS Food and Drug Administration approvalFood and Drug Administration approvalRecurrent thrombosis rateDirect oral anticoagulantsAcute venous thromboembolismNonmajor bleeding eventsPediatric venous thromboembolismDrug Administration approvalFemales aged >Prescribed DOACsDOAC useBleeding complicationsBleeding eventsMenstrual bleedingAnticoagulation regimenDOACsAdministration approvalOff-label
2004
A Potentially Better Means of Preventing Recurrent Venous Thromboembolism Is on the Horizon
Weiss H, Trow T. A Potentially Better Means of Preventing Recurrent Venous Thromboembolism Is on the Horizon. Clinical Pulmonary Medicine 2004, 11: 120-121. DOI: 10.1097/01.cpm.0000117685.82901.2e.Peer-Reviewed Original ResearchVenous thromboembolismOral direct thrombin inhibitor ximelagatranRisk of recurrent thromboembolic eventsSecondary prevention of venous thromboembolismPreventing recurrent venous thromboembolismMonths of anticoagulant therapyPrevention of venous thromboembolismThrombin inhibitor ximelagatranRecurrent venous thromboembolismRecurrent thromboembolic eventsAnticoagulant therapyThromboembolic eventsSecondary preventionThromboembolismXimelagatran
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply